

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Addiese: COMMISSIONER FOR PATENTS P O Box 1450 Alexandra, Virginia 22313-1450 www.upub.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.		
10/807,130	03/23/2004	Jianmmin Shi	ARL 04-16	3686		
21364 U.S. ARMY RI	7590 08/19/201 FSEARCH LABORAT		EXAM	EXAMINER		
ATTN: RDRL	-LOC-I		NWAONICHA,	NWAONICHA, CHUKWUMA O		
2800 POWDER MILL RD ADELPHI, MD 20783-1197			ART UNIT	PAPER NUMBER		
111313131111, 111	320,03 1137		1621			
			MAIL DATE	DELIVERY MODE		
			08/19/2010	PAPER		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)	
Advisory Action	10/807,130	SHI ET AL.	
Before the Filing of an Appeal Brief	Examiner	Art Unit	
	CHUKWUMA O. NWAONICHA	1621	

C	Continuation Sheet (PTOL-303) Application No.	
	The MAILING DATE of this communication appears on the cover sheet with the correspondence address	;
	THE REPLY FILED 15 July 2010 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE.	
	1. \(\sum \) The reply was filed after a final rejection, but prior to or on the same day as filing a Notice of Appeal. To avoid abandon application, applicant must timely file one of the following replies; (1) an amendment, afficiavit, or other evidence, which application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 37 CFR 41.31; or (3) for Continued Examination (RCE) in compliance with 37 CFR 1.114. The reply must be filed within one of the following periods:	n places the a Request
	a) The period for reply expires 2 months from the mailing date of the final rejection.	
	b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whicheven one event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection.	
	Examiner Note: If box 1 is checked, check either box (a) or (b). ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).	
	Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate aware been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate e under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office act set forth in (a) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even i may reduce any earned patient term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL	xtension fee tion; or (2) as
	The Notice of Appeal was filed on, A brief in compliance with 37 CFR 41.37 must be filed within two months of filling the Notice of Appeal (37 CFR 41.37(a), or any extension thereof (37 CFR 41.37(a)), to avoid dismissal of the api Notice of Appeal has been filed, any reply must be filed within the time period set forth in 37 CFR 41.37(a).	the date of peal. Since a
	AMENDMENTS 3. The proposed amendment(s) filed after a final rejection, but prior to the date of filing a brief, will <u>not</u> be entered because (a) They raise new issues that would require further consideration and/or search (see NOTE below):	3 e
	 (b) They raise the issue of new matter (see NOTE below); (c) They are not deemed to place the application in better form for appeal by materially reducing or simplifying the is appeal; and/or 	sues for
	(d) They present additional claims without canceling a corresponding number of finally rejected claims. NOTE:, (See 37 CFR 1.116 and 41.33(a)).	
	4. The amendments are not in compliance with 37 CFR 1.121. See attached Notice of Non-Compliant Amendment (PTO	L-324).
	5. Applicant's reply has overcome the following rejection(s):	
	Newly proposed or amended claim(s) would be allowable if submitted in a separate, timely filed amendment ca non-allowable claim(s).	nceling the
	7. ∑ For purposes of appeal, the proposed amendment(s): a) ☐ will not be entered, or b) ☒ will be entered and an explain how the new or amended claims would be rejected is provided below or appended. The status of the claim(s) is (or will be) as follows:	nation of
	Claim(s) allowed: Claim(s) objected to:	
	Claim(s) rejected: <u>1 and 8-11</u> .	
	Claim(s) withdrawn from consideration:	
	AFFIDAVIT OR OTHER EVIDENCE	
	8. The affidavit or other evidence filed after a final action, but before or on the date of filing a Notice of Appeal will not be because applicant failed to provide a showing of good and sufficient reasons why the affidavit or other evidence is nec was not earlier presented. See 37 CFR 1.116(e).	entered essary and
	9. The affidavit or other evidence filed after the date of filing a Notice of Appeal, but prior to the date of filing a brief, will pentered because the affidavit or other evidence failed to overcome all rejections under appeal and/or appellant fails to showing a good and sufficient reasons why it is necessary and was not earlier presented. See 37 CFR 41.33(a)(1).	
	10. The affidavit or other evidence is entered. An explanation of the status of the claims after entry is below or attached. REQUEST FOR RECONSIDERATION/OTHER	
	11. 🛮 The request for reconsideration has been considered but does NOT place the application in condition for allowance b	
	Applicants' amendment and argument filed 15 July 2010 have been fully considered but they are not persuasive becate Applicants claimed organic luminescent material comprising the general compound of claim 1 is obvious in view of the	iuse
	Applicants calmed origanic uninessent material comprising me general compound or claim 1 is dovious in view or in reference cited. Applicants argue that Jankov Patent 101 presents a myriaed of different compounds all uninessen without teaching or recognizing the use of the claimed anthantherene derivatives as a luminescent dopant material. further argue that the Jankov devices of both the Jankov US '010 and the Jankov EP 1,595,790 teach a two compone material and a dopant, and that Jankov Pub does not teach that the anthantherene derivatives sating alone as the Applicants content that they claim and teach the anthantherene derivatives as the sole luminescent component.	t materials Applicants ent host
	Applicants contend that they claim and teach the anthantherene derivatives as the sole luminescent component. This arguments are not convincing because Applicants claim a luminescent material comprising an anthantherene derivative	s and not a
	Uninescent dopart meterial comprising the an anthanterene derivatives as arqued. Applicants claimed organic lum material comprising the general compound of claim 1; wherein all the other variables are as defined in the claims ove the teachings of Jarikov US '010. The organic luminescent material comprising the general compound of claim 1 as in within the scope of the teachings of the prior art reference cited.	ninescent rlaps with
	12. Note the attached Information Disclosure Statement(s). (PTO/SB/08) Paper No(s).	
	13. Other:	

Continuation Sheet (PTOL-303) Application No.

/Janet L. Andres/ Supervisory Patent Examiner, Art Unit 1625

U.S. Patent and Trademark Office PTOL-303 (Rev. 08-06)

303 (Rev. 08-06) Advisory Action Before the Filing of an Appeal Brief

Part of Paper No. 20100814